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Medication is used in all intensive animal productions. However, the increasing problems with re-
sistant bacteria in all animal productions and in humans are supported by a number of reports. Spe-
cial attention is given to the risk for transmitting food-borne (multi) resistant zoonotic agents to hu-
mans due to failure in antibiotic treatment resulting in lower cure rates or higher case fatality rates. 
The use of medication in humans per se is capable of selecting for resistance in human pathogens.
Nevertheless, the amount of used medication/antimicrobials in treatment of Danish production ani-
mals goes far beyond the amount used for human consumption.
Use of growth promoters was banned by the 31st of August in 1999 in Denmark and an increase in
the use of therapeutic medication was predicted. Nevertheless, the consumption ﬁgures of oral med-
ication from 1999 demonstrated a clear reduction to 37 tons active substance, succeeded by a 50%
increase in 2000 to 56 tons.
The  increase in consumption has not been followed by a similarly increased  mortality, e.g. illus-
trated by the number of rendered animals, increased use of injection medicine for veterinary treat-
ments of diseased animals, or increased number of remarks on the carcasses from the slaughter-
houses. 
The increased use of antibiotics from 1999 to 2000 is predominantly for oral medication on a
farm/herd basis. This type of medication results ﬁrst of all in medicating healthy animals together
with diseased animals. Furthermore, the efﬁciency reports of which the individual farmer is com-
paring his own production results are all based on the maximum achievable growth - a result that of-
ten has been achieved by use of medication. The natural limit of body-growth has been pushed up-
wards during the last decades.  
Detailed studies of the mink production in 1999 and 2000 have revealed that strategic use of antibi-
otics is taking place especially in the weaning and early growth period. However, faecal samples have
demonstrated that presence of haemolytic Staphylococci and haemolytic E. coli was neither associ-
ated with presence of clinical symptoms of diarrhoea nor with increased mortality in the same pe-
riod.  
But, in order to obtain the maximal growth rate in the weaning and growth period mink kits are feed
ad libitum. Furthermore, the composition of the feed is based on test results in order to achieve the
maximum growth and not taking the health of the animals sufﬁciently into account. Hence, the ca-
pacity of growth impairs the health of the animals.
Similar strategies are used in other production systems, where the efﬁciency of the farm is measured
on the basis of the maximum growth rate due to high ﬁxed costs. Medication in animal production
is facing its limits and relevant economic alternatives have to be developed and the strategy for the
future must concentrate on using medication only for clinically diseased animals and not as a strate-
gic treatment of the whole herd in order to maximise growth.
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